Literature DB >> 1299191

Lung dose rate and interstitial pneumonitis in total body irradiation for bone marrow transplantation.

N K Gogna1, G Morgan, K Downs, K Atkinson, J Biggs.   

Abstract

The effect of dose rate to the lungs and development of interstitial pneumonitis (IP) was evaluated in 114 bone marrow transplant patients receiving fractionated total body irradiation (TBI) (1200 rads TD in 6 fractions twice daily over 3 days) as part of their pre-conditioning regimen. The tumour dose (TD) was calculated as the mean lung dose as previously described (1). A 6MV linear accelerator at a mid-line dose rate of 7.5 rads/minute was used between March 1981 and June 1985 and a Co-60 source at 5 rads/minute thereafter. This resulted in a range of dose rates to the lung of between 6.9 and 8.9 rads/minute and 2.9 and 6.5 rads/minute respectively. In the majority of patients the aetiology of IP was investigated by lung biopsy with histology and culture. There was no statistically significant difference in the incidence of IP over the two sets of dose rates. Our study suggest that the incidence of IP using fractionated TBI is not influenced by dose rates below 8.9 rads per minute.

Entities:  

Mesh:

Year:  1992        PMID: 1299191     DOI: 10.1111/j.1440-1673.1992.tb03208.x

Source DB:  PubMed          Journal:  Australas Radiol        ISSN: 0004-8461


  9 in total

1.  Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation: acute parotitis may predict interstitial pneumonitis.

Authors:  Natsuo Oya; Keisuke Sasai; Seiji Tachiiri; Takashi Sakamoto; Yasushi Nagata; Takashi Okada; Shinsuke Yano; Takayuki Ishikawa; Takashi Uchiyama; Masahiro Hiraoka
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

2.  Commissioning of a dedicated commercial Co-60 total body irradiation unit.

Authors:  Jay Burmeister; Adrian Nalichowski; Michael Snyder; Robert Halford; Geoff Baran; Brian Loughery; Ahmad Hammoud; Joe Rakowski; Todd Bossenberger
Journal:  J Appl Clin Med Phys       Date:  2018-03-11       Impact factor: 2.102

3.  The Burden of Survivorship on Hematological Patients-Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation.

Authors:  Michael Oertel; Jonas Martel; Jan-Henrik Mikesch; Sergiu Scobioala; Christian Reicherts; Kai Kröger; Georg Lenz; Matthias Stelljes; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2021-11-11       Impact factor: 6.639

Review 4.  Pulmonary Toxicity After Total Body Irradiation - Critical Review of the Literature and Recommendations for Toxicity Reporting.

Authors:  Jennifer Vogel; Susanta Hui; Chia-Ho Hua; Kathryn Dusenbery; Premavarthy Rassiah; John Kalapurakal; Louis Constine; Natia Esiashvili
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

5.  Adverse Effects of Total Body Irradiation: A Two-Decade, Single Institution Analysis.

Authors:  Richard Pearlman; Renee Hanna; Jay Burmeister; Judith Abrams; Michael Dominello
Journal:  Adv Radiat Oncol       Date:  2021-05-19

6.  Pulmonary Toxicity after Total Body Irradiation-An Underrated Complication? Estimation of Risk via Normal Tissue Complication Probability Calculations and Correlation with Clinical Data.

Authors:  Michael Oertel; Christopher Kittel; Jonas Martel; Jan-Henrik Mikesch; Marco Glashoerster; Matthias Stelljes; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2021-06-12       Impact factor: 6.639

7.  Total body irradiation and pneumonitis risk: a review of outcomes.

Authors:  S A Carruthers; M M Wallington
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

8.  Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation.

Authors:  Dong-Yun Kim; Il Han Kim; Sung-Soo Yoon; Hyoung Jin Kang; Hee Young Shin; Hyun-Cheol Kang
Journal:  Radiat Oncol       Date:  2018-09-18       Impact factor: 3.481

9.  Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?

Authors:  Mitchell Sabloff; Steven Tisseverasinghe; Mustafa Ege Babadagli; Rajiv Samant
Journal:  Curr Oncol       Date:  2021-02-14       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.